{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T04:23:35Z","timestamp":1794543815860,"version":"4.9.1"},"reference-count":62,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010711","name":"Sy\u00f6p\u00e4s\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000027","name":"Institute of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000147","name":"Canadian Cancer Society","doi-asserted-by":"publisher","award":["706667"],"award-info":[{"award-number":["706667"]}],"id":[{"id":"10.13039\/501100000147","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000245","name":"Michael Smith Health Research BC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015803","name":"BC Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015803","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004012","name":"Jane ja Aatos Erkon S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004012","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT 178365"],"award-info":[{"award-number":["PJT 178365"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004376","name":"Terry Fox Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Research Council of Finland","doi-asserted-by":"publisher","award":["352818"],"award-info":[{"award-number":["352818"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Research Council of Finland","doi-asserted-by":"publisher","award":["312043"],"award-info":[{"award-number":["312043"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000015","name":"Canadian Cancer Society Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003125","name":"Suomen Kulttuurirahasto","doi-asserted-by":"publisher","award":["00251012"],"award-info":[{"award-number":["00251012"]}],"id":[{"id":"10.13039\/501100003125","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.annonc.2025.10.1236","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T19:23:02Z","timestamp":1761592982000},"page":"388-402","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1201-6077","authenticated-orcid":false,"given":"T.","family":"Virtanen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.V.W.","family":"Bacon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2150-3139","authenticated-orcid":false,"given":"C.F.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.P.L.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Ryypp\u00f6","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.Q.","family":"Bernales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7373-7567","authenticated-orcid":false,"given":"G.","family":"Donnellan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sipola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5077-2012","authenticated-orcid":false,"given":"J.","family":"Nikkola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5606-0908","authenticated-orcid":false,"given":"G.","family":"Vandekerkhove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4066-885X","authenticated-orcid":false,"given":"S.H.","family":"Tolmeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5819-933X","authenticated-orcid":false,"given":"K.","family":"Kukkonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1490-8131","authenticated-orcid":false,"family":"Adelia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.J.","family":"Eigl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Finch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Gagnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9757-1545","authenticated-orcid":false,"given":"Y.","family":"Takieldeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8910-6332","authenticated-orcid":false,"given":"E.","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Khalaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kollmannsberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-M.","family":"Lavoie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Maurice-Dror","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Nappi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Noonan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Parimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Riminchan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Sartori-Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Soleimani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Vergidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Zulfiqar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Jafri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kolinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.D.","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0347-5541","authenticated-orcid":false,"given":"M.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9845-4603","authenticated-orcid":false,"given":"A.A.N.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Winquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5223-2549","authenticated-orcid":false,"given":"A.M.","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"van der Zande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Zwart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1553-178X","authenticated-orcid":false,"given":"N.P.","family":"van Erp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Rathkopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.E.","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.A.","family":"Quigley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Nykter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.A.","family":"Lack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.N.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8478-9026","authenticated-orcid":false,"given":"M.","family":"Annala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2399-0329","authenticated-orcid":false,"given":"A.W.","family":"Wyatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10305","key":"10.1016\/j.annonc.2025.10.1236_bib1","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00950-8","article-title":"Prostate cancer","volume":"398","author":"Sandhu","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.annonc.2025.10.1236_bib2","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"suppl 6","key":"10.1016\/j.annonc.2025.10.1236_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1200\/JCO.2022.40.6_suppl.017","article-title":"Phase 1\/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC)","volume":"40","author":"Gao","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.annonc.2025.10.1236_bib4","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2024.42.4_suppl.134","article-title":"First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"42","author":"Rathkopf","year":"2024","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2025.10.1236_bib5","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"suppl 1","key":"10.1016\/j.annonc.2025.10.1236_bib6","first-page":"S25","article-title":"Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer","volume":"82","author":"Kwan","year":"2022","journal-title":"Prostate"},{"issue":"5","key":"10.1016\/j.annonc.2025.10.1236_bib7","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"23","key":"10.1016\/j.annonc.2025.10.1236_bib8","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.annonc.2025.10.1236_bib9","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41588-018-0078-z","article-title":"The long tail of oncogenic drivers in prostate cancer","volume":"50","author":"Armenia","year":"2018","journal-title":"Nat Genet"},{"issue":"7921","key":"10.1016\/j.annonc.2025.10.1236_bib10","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41586-022-04975-9","article-title":"Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer","volume":"608","author":"Herberts","year":"2022","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.annonc.2025.10.1236_bib11","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nm.4053","article-title":"Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer","volume":"22","author":"Kumar","year":"2016","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.annonc.2025.10.1236_bib12","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcad045","article-title":"Co-evolution of AR gene copy number and structural complexity in endocrine therapy resistant prostate cancer","volume":"5","author":"Zivanovic","year":"2023","journal-title":"NAR Cancer"},{"issue":"4","key":"10.1016\/j.annonc.2025.10.1236_bib13","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/ng0495-401","article-title":"In vivo amplification of the androgen receptor gene and progression of human prostate cancer","volume":"9","author":"Visakorpi","year":"1995","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.annonc.2025.10.1236_bib14","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.cell.2018.05.037","article-title":"A somatically acquired enhancer of the androgen receptor is a noncoding driver in advanced prostate cancer","volume":"174","author":"Takeda","year":"2018","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.annonc.2025.10.1236_bib15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cell.2018.05.036","article-title":"Structural alterations driving castration-resistant prostate cancer revealed by linked-read genome sequencing","volume":"174","author":"Viswanathan","year":"2018","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.annonc.2025.10.1236_bib16","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.cell.2018.06.039","article-title":"Genomic hallmarks and structural variation in metastatic prostate cancer","volume":"174","author":"Quigley","year":"2018","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.annonc.2025.10.1236_bib17","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0006-291X(05)80067-1","article-title":"A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens","volume":"173","author":"Veldscholte","year":"1990","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"10.1016\/j.annonc.2025.10.1236_bib18","first-page":"1383","article-title":"Functional characterization of mutant androgen receptors from androgen-independent prostate cancer","volume":"3","author":"Fenton","year":"1997","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.annonc.2025.10.1236_bib19","first-page":"2511","article-title":"Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist","volume":"59","author":"Taplin","year":"1999","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.1236_bib20","first-page":"149","article-title":"Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome","volume":"63","author":"Hara","year":"2003","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.annonc.2025.10.1236_bib21","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1210\/en.2017-00109","article-title":"Androgen receptor rearrangement and splicing variants in resistance to endocrine therapies in prostate cancer","volume":"158","author":"Ho","year":"2017","journal-title":"Endocrinology"},{"issue":"8","key":"10.1016\/j.annonc.2025.10.1236_bib22","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1158\/1078-0432.CCR-19-3023","article-title":"Diverse AR gene rearrangements mediate resistance to androgen receptor inhibitors in metastatic prostate cancer","volume":"26","author":"Li","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"16","key":"10.1016\/j.annonc.2025.10.1236_bib23","doi-asserted-by":"crossref","first-page":"4610","DOI":"10.1158\/1078-0432.CCR-21-1625","article-title":"Evolution of castration-resistant prostate cancer in ctDNA during sequential androgen receptor pathway inhibition","volume":"27","author":"Annala","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2025.10.1236_bib24","article-title":"Prevalence and spectrum of AR ligand-binding domain mutations detected in circulating-tumor DNA across disease states in men with metastatic castration-resistant prostate cancer","volume":"8","author":"Antonarakis","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2025.10.1236_bib25","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1158\/1078-0432.CCR-20-4805","article-title":"Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms","volume":"27","author":"Tukachinsky","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.annonc.2025.10.1236_bib26","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1634\/theoncologist.2019-0115","article-title":"Comprehensive analysis of AR alterations in circulating tumor DNA from patients with advanced prostate cancer","volume":"25","author":"Ledet","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.annonc.2025.10.1236_bib27","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1200\/PO.20.00084","article-title":"A systematic review and meta-analysis on the predictive value of cell-free DNA-based androgen receptor copy number gain in patients with castration-resistant prostate cancer","volume":"4","author":"Tolmeijer","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2025.10.1236_bib28","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/2159-8290.CD-17-0937","article-title":"Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer","volume":"8","author":"Annala","year":"2018","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.annonc.2025.10.1236_bib29","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1158\/1078-0432.CCR-18-1943","article-title":"TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer","volume":"25","author":"De Laere","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.1236_bib30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.eururo.2021.09.030","article-title":"Predictive genomic biomarkers of hormonal therapy versus chemotherapy benefit in metastatic castration-resistant prostate cancer","volume":"81","author":"Graf","year":"2022","journal-title":"Eur Urol"},{"issue":"312","key":"10.1016\/j.annonc.2025.10.1236_bib31","doi-asserted-by":"crossref","first-page":"312re10","DOI":"10.1126\/scitranslmed.aac9511","article-title":"Plasma AR and abiraterone-resistant prostate cancer","volume":"7","author":"Romanel","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.annonc.2025.10.1236_bib32","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.euros.2023.05.008","article-title":"AR and PI3K genomic profiling of cell-free DNA can identify poor responders to lutetium-177-PSMA among patients with metastatic castration-resistant prostate cancer","volume":"53","author":"Vanwelkenhuyzen","year":"2023","journal-title":"Eur Urol Open Sci"},{"issue":"11","key":"10.1016\/j.annonc.2025.10.1236_bib33","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1038\/s41591-024-03204-2","article-title":"Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial","volume":"30","author":"De Laere","year":"2024","journal-title":"Nat Med"},{"issue":"16","key":"10.1016\/j.annonc.2025.10.1236_bib34","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1002\/pros.24618","article-title":"Impact of androgen receptor alterations on cell-free DNA genomic profiling on survival outcomes in metastatic castration-resistant prostate cancer","volume":"83","author":"Tripathi","year":"2023","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.1236_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54847-1","article-title":"AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients","volume":"15","author":"Knutson","year":"2024","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.annonc.2025.10.1236_bib36","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1001\/jamaoncol.2024.7051","article-title":"Plasma AR alterations and timing of intensified hormone treatment for prostate cancer: The STAMPEDE phase 3 randomized clinical trial","volume":"11","author":"Leone","year":"2025","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2025.10.1236_bib37","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/S1470-2045(19)30688-6","article-title":"Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial","volume":"20","author":"Khalaf","year":"2019","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2025.10.1236_bib38","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.annonc.2021.03.205","article-title":"Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial","volume":"32","author":"Annala","year":"2021","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.annonc.2025.10.1236_bib39","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1158\/1078-0432.CCR-22-2998","article-title":"Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer","volume":"29","author":"Tolmeijer","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2025.10.1236_bib40","doi-asserted-by":"crossref","first-page":"10463","DOI":"10.2147\/CMAR.S208720","article-title":"First-in-human phase I study of a dual mTOR kinase and DNA-PK inhibitor (CC-115) in advanced malignancy","volume":"11","author":"Munster","year":"2019","journal-title":"Cancer Manag Res"},{"issue":"suppl 5","key":"10.1016\/j.annonc.2025.10.1236_bib41","article-title":"CCTG IND 232: a phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC)","volume":"30","author":"Hotte","year":"2019","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.annonc.2025.10.1236_bib42","doi-asserted-by":"crossref","DOI":"10.1172\/JCI178604","article-title":"Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer","volume":"134","author":"Zhu","year":"2024","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.annonc.2025.10.1236_bib43","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.ajhg.2021.11.007","article-title":"H3K27ac HiChIP in prostate cell lines identifies risk genes for prostate cancer susceptibility","volume":"108","author":"Giambartolomei","year":"2021","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.1016\/j.annonc.2025.10.1236_bib44","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/neuonc\/nos299","article-title":"Wnt\/\u03b2-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells","volume":"15","author":"Kim","year":"2013","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2025.10.1236_bib45","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41391-024-00869-1","article-title":"Clinical implications of Wnt pathway genetic alterations in men with advanced prostate cancer","volume":"28","author":"Broderick","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"10.1016\/j.annonc.2025.10.1236_bib46","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/genetics\/26.2.234","article-title":"The stability of broken ends of chromosomes in Zea Mays","volume":"26","author":"McClintock","year":"1941","journal-title":"Genetics"},{"issue":"6","key":"10.1016\/j.annonc.2025.10.1236_bib47","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3362","article-title":"A common copy-number breakpoint of ERBB2 amplification in breast cancer colocalizes with a complex block of segmental duplications","volume":"14","author":"Marotta","year":"2012","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.1236_bib48","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/s41598-020-80948-0","article-title":"Detectable chromosome X mosaicism in males is rarely tolerated in peripheral leukocytes","volume":"11","author":"Zhou","year":"2021","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.annonc.2025.10.1236_bib49","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1038\/s41588-024-01949-7","article-title":"Mapping extrachromosomal DNA amplifications during cancer progression","volume":"56","author":"Kim","year":"2024","journal-title":"Nat Genet"},{"issue":"7","key":"10.1016\/j.annonc.2025.10.1236_bib50","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.cell.2018.04.034","article-title":"Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer","volume":"173","author":"Wu","year":"2018","journal-title":"Cell"},{"issue":"D1","key":"10.1016\/j.annonc.2025.10.1236_bib51","first-page":"D174","article-title":"PolyASite 2.0: a consolidated atlas of polyadenylation sites from 3\u2019 end sequencing","volume":"48","author":"Herrmann","year":"2020","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"10.1016\/j.annonc.2025.10.1236_bib52","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1172\/JCI41824","article-title":"Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant","volume":"120","author":"Sun","year":"2010","journal-title":"J Clin Invest"},{"issue":"23","key":"10.1016\/j.annonc.2025.10.1236_bib53","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M112.352930","article-title":"Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal","volume":"287","author":"Chan","year":"2012","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.annonc.2025.10.1236_bib54","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41568-022-00481-2","article-title":"Nonsense-mediated RNA decay: an emerging modulator of malignancy","volume":"22","author":"Tan","year":"2022","journal-title":"Nat Rev Cancer"},{"issue":"21","key":"10.1016\/j.annonc.2025.10.1236_bib55","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJM199505253322101","article-title":"Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer","volume":"332","author":"Taplin","year":"1995","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.annonc.2025.10.1236_bib56","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1158\/1078-0432.CCR-14-1220","article-title":"Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors","volume":"21","author":"Chen","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.annonc.2025.10.1236_bib57","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.euo.2024.04.011","article-title":"Prognostic and predictive role of SPOP mutations in prostate cancer: a systematic review and meta-analysis","volume":"7","author":"Pedrani","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2025.10.1236_bib58","first-page":"3777","article-title":"Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production, and male infertility","volume":"82","author":"Tut","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"24","key":"10.1016\/j.annonc.2025.10.1236_bib59","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1038\/sj.onc.1209366","article-title":"Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells","volume":"25","author":"Yang","year":"2006","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.annonc.2025.10.1236_bib60","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/cancers9020014","article-title":"A tale of two signals: AR and WNT in development and tumorigenesis of prostate and mammary gland","volume":"9","author":"Pakula","year":"2017","journal-title":"Cancers (Basel)"},{"issue":"39","key":"10.1016\/j.annonc.2025.10.1236_bib61","doi-asserted-by":"crossref","first-page":"16759","DOI":"10.1073\/pnas.1012443107","article-title":"Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor","volume":"107","author":"Watson","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.1236_bib62","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.annonc.2024.09.005","article-title":"Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer","volume":"36","author":"Rathkopf","year":"2025","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425061885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425061885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T14:40:32Z","timestamp":1773931232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753425061885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0923753425061885"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.10.1236","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.10.1236","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}